Sanofi India is currently trading at Rs. 3495.00, up by 44.25 points or 1.28% from its previous closing of Rs. 3450.75 on the BSE.
The scrip opened at Rs. 3503.90 and has touched a high and low of Rs. 3513.00 and Rs. 3443.00 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3693.80 on 25-Sep-2014 and a 52 week low of Rs. 2500.00 on 17-Feb-2014.
Last one week high and low of the scrip stood at Rs. 3605.60 and Rs. 3412.00 respectively. The current market cap of the company is Rs. 8,048.00 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 28.62% and 10.99% respectively.
Sanofi India has received an approval for selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments and its Group companies for a total consideration of Rs 134.25 crore. The board of directors at their meeting held on November 11, 2014 has approved for the same.
Each floor admeasures 7,442 square feet carpet area and all the floors have presently been given out on leave and license basis by the company to various third parties. The transaction is expected to be completed in the quarter ending December 31, 2014.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: